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Genetically Modified NT2N Human Neuronal Cells Mediate Long-Term Gene Expression as
CNS Grafts In Vivo and Improve Functional Cognitive Outcome Following Experimental
Traumatic Brain Injury
DEBORAH J. WATSON, PHD, LUCA LONGHI, MD, EDWARD B. LEE, BS, CARL T. FULP, BS, SCOTT FUJIMOTO, BS,
NICOLAS C. ROYO, PHD, MARCO A. PASSINI, PHD, JOHN Q. TROJANOWSKI, MD, PHD, VIRGINIA M.-Y. LEE, PHD,
TRACY K. MCINTOSH, PHD, AND JOHN H. WOLFE, VMD, PHD
Abstract. Human Ntera-2 (NT2) cells can be differentiated in vitro into well-characterized populations of NT2N neurons
that engraft and mature when transplanted into the adult CNS of rodents and humans. They have shown promise as treatments
for neurologic disease, trauma, and ischemic stroke. Although these features suggest that NT2N neurons would be an excellent
platform for ex vivo gene therapy in the CNS, stable gene expression has been surprisingly difficult to achieve in these cells.
In this report we demonstrate stable, efficient, and nontoxic gene transfer into undifferentiated NT2 cells using a pseudotyped
lentiviral vector encoding the human elongation factor 1-a promoter and the reporter gene eGFP. Expression of eGFP was
maintained when the NT2 cells were differentiated into NT2N neurons after treatment with retinoic acid. When transplanted
into the striatum of adult nude mice, transduced NT2N neurons survived, engrafted, and continued to express the reporter
gene for long-term time points in vivo. Furthermore, transplantation of NT2N neurons genetically modified to express nerve
growth factor significantly attenuated cognitive dysfunction following traumatic brain injury in mice. These results demonstrate
that defined populations of genetically modified human NT2N neurons are a practical and effective platform for stable ex
vivo gene delivery into the CNS.
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INTRODUCTION
The Ntera-2 (NT2) cell line is a unique human cell
line that terminally differentiates exclusively into post-
mitotic neurons (designated as NT2N neurons) when ex-
posed to retinoic acid in vitro and has been widely used
for experiments in developmental neurobiology (1–5).
NT2N neurons have particular advantages for studies of
neural transplantation. NT2 cells are differentiated into
.95% NT2N neurons in vitro before transplantation (2,
6, 7), generating a uniform population of human cells
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whose neuronal fate is already specified, but which none-
theless respond to the local environment by assuming cel-
lular morphologies and processes appropriate to the re-
gion into which they are engrafted (7). In contrast, neural
stem cells can give rise to multiple lineages, but they rely
on local cues in the recipient nervous system to specify
their phenotype. In many regions of the post-natal CNS,
transplanted neural stem cells differentiate predominantly
into glia (8–10).
The NT2N neurons are an unlimited source of human
cells that can be produced under good manufacturing
practice conditions suitable for human clinical trials.
They thus represent a potentially better alternative to oth-
er sources currently under investigation for CNS trans-
plantation, including human embryonic stem cells, xe-
nografts, and fetal mesencephalic cells (11, 12). Grafts of
differentiated NT2N neurons in the CNS are stable and
appear to be safe since they have not been found to de-
differentiate or to form tumors in vivo for at least 1 year
post-transplantation in mice or humans (13–15). The
grafted neurons develop a mature neuronal phenotype in
vivo, based on axonal and dendritic polarity, synaptophy-
sin expression, region-specific process outgrowth, and ev-
idence of synaptic vesicle formation, suggesting that the
grafts may contain functional neurons (6, 7, 16).
Purified NT2N neurons have been used to study the
ability of neuronal CNS grafts to restore function in an-
imal models of neurodegenerative disease and trauma
(17–21). Particularly promising results were obtained in
a model of ischemia (22). Based on this work and other
preclinical studies, a phase I human clinical trial was ini-
tiated in which 12 patients with basal ganglia stroke were
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transplanted with NT2N neurons. Evidence for survival
of the grafts has been obtained by imaging techniques at
1 year post-transplant (23) and in 1 postmortem case at
27 months post-transplant (15). Some of the patients
showed improvement of motor function outcome scores
(14), suggesting the possibility that the transplant may
mediate this effect, but this was a phase I safety trial with
too few patients to establish efficacy. However, all of the
rodent and human studies to date have relied on the en-
dogenous properties of the NT2N neurons for any ther-
apeutic effect.
The combination of these factors—the ability to spec-
ify the neuronal fate of these cells before transplantation,
the fact that grafts of NT2N neurons develop markers of
mature CNS neurons in vivo, and the fact that the grafts
are stable and nontumorigenic—strongly suggests that
NT2N neurons could represent an excellent platform for
therapeutic gene transfer into the CNS. However, previ-
ous attempts to genetically modify NT2 cells by trans-
fection or viral vector transduction (2, 24–26) have met
with only limited success, i.e. low efficiency of gene
transfer, low levels of expression or only transient ex-
pression. Consequently, no attempts to transplant genet-
ically modified NT2N neurons have been reported.
In this study we demonstrate efficient, stable, and non-
toxic transduction of undifferentiated NT2 cells, using a
self-inactivating lentiviral vector encoding the eGFP re-
porter gene (27). A constitutively active eukaryotic pro-
moter (human elongation factor 1-a) resulted in stable
eGFP reporter gene expression both in undifferentiated
NT2 cells and also after the transduced cells were dif-
ferentiated into NT2N neurons in vitro. Furthermore, the
genetically modified neurons continued to express the re-
porter gene at long post-transplantation time points in the
adult nude mouse brain.
Neural transplantation is one potential strategy for re-
storing cognitive and motor function following traumatic
brain injury (TBI). Potential therapeutic effects of neural
grafts may result from either functional replacement of
dying neurons, or from support of endogenous injured
cells by trophic factors secreted from the neural graft, or
both. To distinguish between these mechanisms, we used
a lentiviral vector to introduce the coding sequence for
nerve growth factor (NGF) into NT2N neurons. Previous
work from our lab and others has indicated that admin-
istration of NGF may attenuate cell death and improve
behavioural dysfunction when administered 24 hours (h)
following brain injury in rats. However, the severe side
effects of neurotrophin infusion have led us to investigate
methods for regional delivery of NGF. We hypothesized
that using NT2N neurons to deliver the growth factor
locally would provide an advantage for long-term neu-
rotrophin delivery into selectively vulnerable regions of
the injured brain.
In this report, transduced or untransduced neurons
were engrafted into the injured CNS of mice that had
been subjected to experimental TBI. Transplanted and
control mice were tested for their ability to learn in the
Morris Water Maze. We found that transduced NT2N
neurons expressing NGF significantly improved learning
in brain-injured mice at 1 month post-injury.
These results show that genetically modified NT2N
neurons represent a practical new method for ex vivo
gene delivery in the CNS. Homogeneous populations of
these genetically modified human neurons should be of
great utility for introducing therapeutic genes into the
adult CNS.
MATERIALS AND METHODS
Virus Production
HEK 293T cells were plated on poly-D-lysine-coated 10-cm
plates. One day later, the cells were transfected with 5 mg of
pMD.G (encoding the VSV-G envelope glycoprotein [28]), 15
mg of pCMVDR8.2 (encoding viral structural, enzyme, and ac-
cessory genes [28]) and 20 mg of the transfer plasmid (SIN-
EF-nLacZ, gift of Dr. Lung-Ji Chang, University of Florida
[27]), using the CalPhos Transfection Kit (Clontech, Palo Alto,
CA). The SIN-EF-NGF-IRES-eGFP transfer plasmid was con-
structed by ligating the following fragments into pTYlinker (gift
of L. Chang): 1) the human EF1a promoter (1.5 kb NotI frag-
ment from pTY-EF-eGFP, gift of L. Chang); 2) the human NGF-
b coding sequence from plasmids N8D8 and N8B9 (ATCC),
amplified with primers 59-TCAATGAGCTAGCATGTCCAT
GTTGT-39 and 59-GATCAAGCTAGCTCAGGCTCTTCT-39 to
introduce NheI restriction sites; 3) the XhoI-XbaI fragment of
pIRES (Clontech) containing the 638 bp internal ribosome entry
site (IRES); and 4) the XbaI-EcoRI fragment encoding the 787
bp humanized eGFP coding sequence from pTY-EF-eGFP.
After transfection the cells were rinsed and the medium was
replaced with OptiMem Reduced Serum Medium (Gibco BRL,
Gaithersburg MD) 12 to 16 h later. Viral supernatants were
collected every 24 h for 3 to 5 days, centrifuged at 1,000 rpm
for 5 min at 48C, and passed through a 0.45 mm filter to remove
any remaining producer cells. Unconcentrated vector stocks
were used for transduction and titering immediately after col-
lection. Titering of marker vectors was performed on human
293T cells in the presence of 8 mg/ml polybrene (Sigma, St.
Louis, MO) and titers were determined by counting the number
of eGFP-positive cells 48 h later, or by reacting the cells with
X-gal according to standard methods 48 h after transduction.
No polybrene was used for transduction of undifferentiated
NT2 cells.
Maintenance and Differentiation of NT2 Cells
Undifferentiated NT2 cells were maintained in growth me-
dium (OptiMem with 5% fetal bovine serum, 100 U/ml peni-
cillin, and 100 mg/ml streptomycin sulfate) and passaged twice
weekly at a ratio of 1:4. For transplantation, NT2 cells were
differentiated into NT2N neurons as described (29). Briefly, 2.3
3 106 cells were exposed to 10 mM retinoic acid (Sigma) for
5 weeks in growth medium, then the cells were changed to
DMEM with high glucose, 5% serum, and mitotic inhibitors
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(10 mM uridine, 10 mM 5-fluoro-29deoxyuridine, 1 mM cytosine
arabinoside, all from Sigma) for 10 to 13 days. NT2N neurons
are purified from remaining undifferentiated epithelial-like cells
by serial replating and are collected for transplantation at the
replate III stage when they are approximately 95% pure (29).
For in vitro differentiation experiments, NT2 cells were plated
on a monolayer of rat astrocytes and cultured for up to 4 weeks.
Immunochemistry
Cells on coverslips were fixed in fresh 4% paraformaldehyde
(pH 7.4) for 10 min, rinsed, permeabilized with 0.2% Triton X-
100 for 10 min, rinsed, blocked in 5% donkey serum in PBS
for 1 h, then exposed to the primary antibody 3 h at room
temperature (RT) or overnight at 48C. For immunofluorescence
analysis, frozen sections were hydrated in 0.1 M Tris pH 7.4
for 5 min at RT and blocked in 0.1 M Tris with 2% IgG-free
donor horse serum (DHS) for 5 min at RT. Sections were ex-
posed to primary antibody overnight at 48C. After a 5-min 0.1
M Tris wash, and a 5-min blocking step in 2% DHS, secondary
antibody was applied for 1 h at RT. Sections were then washed
in 0.1 M Tris at RT with gentle agitation twice for 20 min each.
Primary antibodies were rabbit anti-eGFP (IgG fraction 1:200,
Molecular Probes, Eugene, OR) and rat anti-human neurofila-
ment (HO14, used neat; [4]). Secondary antibodies for immu-
nofluorescence were Texas Red-coupled donkey anti-rat (1:400)
and FITC-coupled donkey anti-rabbit (1:100) purchased from
Jackson Immunoresearch Laboratories (West Grove, PA). Slides
were coverslipped in Vectashield fluorescence mounting media
containing DAPI (Vector Laboratories, Burlingame, CA). For
immunohistochemistry, sections were deparaffinized in xylene
(2 3 5 min), hydrated through graded alcohols, incubated in
methanol with 5% H2O2 to block endogenous peroxidase activ-
ity, washed in running H2O (10 min) and 0.1 M Tris pH 7.6 (5
min), blocked in 2% DHS (5 min), incubated with undiluted
HO14 primary antibody overnight at 48C. Sections were rinsed
in 0.1 M Tris (5 min), blocked in 2% DHS (5 min), and incu-
bated with the secondary antibody (biotinylated anti-rat IgG, 1:
1,000, Vector Labs) for 1 h at RT. Sections were washed and
blocked as above and incubated with ABC reagent (1 h at RT,
Vector Labs), washed and developed with diaminobenzidine so-
lution, rinsed and counterstained with Harris’ hematoxylin. Dig-
ital photomicrographs were acquired with a Zeiss Axiophot mi-
croscope, a Toshiba 3CCD camera, and ImagePro software.
Transplants in Nude Mice
Surgeries were performed as described (30). Ten to 20,000
NT2N neurons in 1 ml culture medium were transplanted into
the striatum of adult female nude mice using stereotaxic coor-
dinates (DV: 2.5 mm, ML: 2 mm, AP: on bregma) (31). Trans-
plants were bilateral, with untransduced neurons on the right
and transduced neurons on the left. Mice were killed at 1 week,
1 month, or 22 weeks post-transplant. Mice were deeply anes-
thetized with ketamine and xylazine and perfused with PBS
followed by 4% paraformaldehyde (pH 7.4) for paraffin em-
bedding, or perfused with PBS and brains were immersion-fixed
in 4% paraformaldehyde overnight, cryoprotected in 30% su-
crose, and frozen for cryosectioning. Brains were unilaterally
notched before embedding to ensure that right and left sides
were identifiable. To obtain control sections for anti-eGFP im-
munohistochemistry and in situ hybridization, mice were in-
jected (directly transduced) with a CMV-eGFP encoding lenti-
viral vector. For all injections, a 30-gauge blunt or beveled
needle was attached to a 10-ml Hamilton syringe. Injections
were performed at 1 ml/min.
In Situ Hybridization
For detection of eGFP mRNA or human NGF mRNA, the
coding sequences were cloned into pBluescript II KS1 (Stra-
tagene, La Jolla, CA) to generate antisense and control sense
eGFP riboprobes (731 bp each) or 841-bp NGF antisense and
760-bp control sense NGF riboprobes. Nonradioactive in situ
hybridization histochemistry was performed as described (32),
except that paraffin-embedded tissue sections were first depar-
affinized in 100% xylene (3 3 5 min) and 100% ethanol (1 3
1 min).
Assays for NGF Concentration and Bioactivity
PC12 survival and neurite regeneration assays were per-
formed as described (33). Plates were coated with rat tail col-
lagen (Collaborative Biomedical Products, Bedford, MA). Con-
ditioned medium was obtained by incubating serum-free RPMI
with 293T cells that had been transfected with the lentiviral
transfer plasmid or control untransfected cells. For survival
studies, naive PC12 cells were washed 5 times to remove serum
and plated in serum-free RPMI medium alone or containing
either 50 ng/ml recombinant human b-NGF (Chemicon, Te-
mecula, CA) or 50% conditioned medium. For neurite regen-
eration assays, PC12 cells were primed by culturing in serum-
containing medium with NGF for 1 week, then shearing off the
processes by trituration and replating in serum-free medium
alone or supplemented with 50% conditioned medium from
NGF-transfected or untransfected cells. Cells were examined at
72 h after treatment. The amount NGF secreted from transduced
NT2 cells was determined with the NGF Emax ImmunoAssay
System (Promega, Madison, WI) according to the manufactur-
er’s instructions. Conditioned media was diluted until the ab-
sorbance readings were in the linear range of the assay.
Controlled Cortical Impact (CCI) Brain Injury
All the animal procedures were conducted in strict accor-
dance with the National Institutes of Health Guide for the Care
and Use of Laboratory Animals and approved by the Institu-
tional Animal Care and Use Committee of the Veteran’s Ad-
ministration Medical Center of Philadelphia. A total of 32 adult
male C57Bl/6 mice (19–24 g) were used for this study. Mice
were anesthetized with intraperitoneal administration of sodium
pentobarbital (65 mg/kg, Nembutal Sodium Solution, Abbott
Laboratories, North Chicago, IL), and placed in a stereotactic
frame. As described by our laboratory (34), a midline scalp
incision was made to expose the skull and then, by trephination,
a 5-mm rounded bone flap was removed from the center of the
left parietal bone without damaging the underlying dura mater.
Forty-five minutes after induction of the anesthesia the mice
were subjected to controlled cortical impact (CCI) brain injury.
Sham-injured control animals received the same anesthesia and
the same surgical procedure (craniectomy), but were not sub-
jected to brain injury.
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This model of injury uses a 3-mm impounder driven by a
pneumatic piston, rigidly mounted at an angle of 208 from the
vertical plane and applied perpendicularly to the exposed dura
mater over the left parieto-temporal cortex between bregma and
lambda, at a velocity of 4.8 to 5.0 m/s and a 1-mm depth of
deformation (35). After the procedure the craniotomy was cov-
ered with a cranioplasty and the scalp sutured. During surgery
and recovery the mice were placed over a heating pad and
maintained at 378C.
Transplantation into Brain-Injured Mice
All cells for these experiments were grown, differentiated,
harvested, and frozen in aliquots (in 95% serum 1 5% DMSO)
at the same time in order to create a uniform population for
later transplantation. For transplantation, individual aliquots of
NGF-expressing and control-untransduced NT2N neurons were
thawed at 358C, added to 5 ml DMEM to dilute the DMSO,
collected by centrifugation, washed, and resuspended in serum-
free DMEM. One ml of the cell suspension was added to 9 ml
of trypan blue for cell counting and assessment of viability
(range, 71.2%–80.8%). Yields were typically 15,000 to 20,000
live cells in 2 ml. Cells were kept on ice during the injection
procedure for a total of less than 1.5 h. Separate aliquots of
serum-free DMEM were used for the vehicle controls.
Twenty-four hours after CCI brain injury, all animals were
subjected to cell transplantation or injection of the same me-
dium in which the NT2N neurons were resuspended (vehicle
controls). Animals were divided into 4 groups: 1) sham-injured
animals (surgery without injury) injected with medium; 2) CCI-
injured animals injected with medium; 3) CCI-injured mice en-
grafted with untransduced NT2N neurons; or 4) CCI-injured
mice engrafted with NGF-transduced NT2N neurons. A ran-
domized set of animals from each of the 4 experimental groups
were injected on a given day and the vials of cells and media
were coded so that the surgeon (L.L.) was blinded to the treat-
ment status of each animal. The injection was performed at the
following stereotaxic coordinates: anterior-posterior (AP), breg-
ma 1 0.7 mm; medial-lateral (ML), 0.2 mm over the injured
hemisphere; dorso-ventral (DV), 3.7 mm from the skull (31)
with a 10-ml Hamilton syringe fitted with a 30-gauge beveled
needle. These coordinates target the medial septal nucleus,
which is located ventral and rostral to the cortical injury cavity
and the hippocampus and contains the cell bodies of cholinergic
septo-hippocampal projection neurons that are normally sus-
tained by retrograde NGF trophic support from the hippocam-
pus (Fig. 4). Each animal was injected with 2 microliters of cell
suspension or medium at 1 ml/min using a microprocessor-con-
trolled pump (UltraMicroPump II, World Precision Instruments,
Inc, Sarasota, FL). After the injection the syringe was left in
place for 5 min and then gently retracted to avoid a negative
pressure-driven dispersion of the cells or vehicle upward along
the needle tract. This paradigm has been used successfully in
our laboratory previously for transplantation of NT2N cells (18,
19). At the end of the procedure the scalp was sutured and mice
were allowed to recover over a heating pad maintained at 378C
degrees. To prevent rejection of the human NT2N cells, all an-
imals, regardless of treatment status, received daily intraperi-
toneal injections of cyclosporin A (CsA, 10 mg/kg) beginning
at 1 h post-injury for the duration of the study.
Behavioral Analysis
Evaluation of cognitive function was performed using the
Morris Water Maze. Our Morris Water Maze is a white circular
pool (1-meter diameter) filled with water (188C–208C) that is
made opaque by adding nontoxic water-soluble white paint. The
task requires that the animals learn to locate a submerged plat-
form placed 0.5 cm under the surface of the water using exter-
nal visual cues after being randomly placed at 1 of 4 sites in
the pool. Latencies to reach and climb onto the platform were
recorded for each trial, with a maximal allowed time of 60
seconds. Mice were evaluated for post-injury learning at 4
weeks post-transplantation with 8 trials/day for 3 days. At this
time point, CCI-injured mice show significant learning deficits
when compared with sham-injured animals (unpublished data).
Injured and sham-injured mice do not differ in their swim
speeds or paths in this model of TBI (35). Since this experiment
was designed to test learning (acquisition) and not working
memory, analysis of path length and duration of time spent in
each quadrant were not measured in this study.
Statistical Analysis
Learning latencies are presented as mean 6 standard error of
the mean. The comparison between groups was performed us-
ing a multivariate ANOVA followed by a Tukey-Kramer mul-
tiple comparison test. A probability value less than 0.05 is con-
sidered statistically significant.
RESULTS
Stable Transduction of NT2 Cells by a Lentiviral Vector
Undifferentiated NT2 cells were exposed to an HIV-
based, self-inactivating (SIN) lentiviral vector pseudoty-
ped with the vesicular stomatitis virus surface glycopro-
tein (VSV-G). The human elongation factor 1a promoter
(EF1a) was used to express enhanced GFP (SIN-EF-
eGFP) or NGF (Fig. 1A). Strong eGFP fluorescence was
observed in the cells exposed to the SIN-EF-eGFP len-
tiviral vector (Fig. 1B), indicating highly efficient trans-
duction.
Generation of Transduced NT2N Neurons In Vitro
To determine if eGFP expression driven by the EF1a
promoter was maintained in differentiated NT2N neu-
rons, transduced or untransduced NT2 cells were differ-
entiated in vitro on an astrocyte monolayer. This method
allows differentiation to be followed in vitro over time,
although the neurons cannot be harvested for transplan-
tation. After 7 days of coculture, the transduced NT2 cells
extended processes that were eGFP-immunoreactive and
also immunoreactive with a human-specific anti-neurofil-
ament antibody, consistent with nascent NT2N neurons
(Fig. 2A–D). In the transduced neurons, eGFP-immuno-
reactivity was detected in the cell bodies and throughout
the processes (Fig. 2B, C, E, F). Control untransduced
cells (Fig. 2G) extended processes that reacted with the
human neurofilament antibody (Fig. 2H) but were not
372 WATSON ET AL
J Neuropathol Exp Neurol, Vol 62, April, 2003
Fig. 1. Transduction of undifferentiated NT2 cells. A: Schematic representation of the self-inactivating (SIN) transfer vectors
used in this study. Upper: SIN-EF-eGFP, Lower: SIN-EF-NGF-IRES-eGFP. B: Expression of eGFP (green) in cells transduced
with SIN-EF-eGFP. Nuclei were stained with DAPI (blue). Scale bar, 20 mm.
eGFP-positive. These results indicate that the EF1a pro-
moter remained active after the cells were differentiated
into neurons and can be used to drive constitutive ex-
pression of foreign genes in NT2N neurons in vitro.
Transduced neurons were followed over time to deter-
mine the duration of eGFP expression in vitro. After 2
or 4 weeks of differentiation, the NT2N neurons were
stained with an anti-human neurofilament antibody
(huNF-M, HO14) and an anti-eGFP antibody (Fig. 2I–
K). After 4 weeks in culture, HO-14-positive processes
were substantially longer than at 1 week (compare Fig.
2I to 2C) and the morphology of transduced neurons was
more complex, often with multiple branched processes
(Fig. 2I–K, insets). We compared the percentages of
eGFP-expressing cells before and after differentiation to
examine the possibility of down-regulation of eGFP ex-
pression in the neurons. In the starting population of
transduced undifferentiated NT2 cells, 29.1 6 3.2 ex-
pressed eGFP (mean 6 SEM, n 5 735 cells counted).
After differentiation, the percentage of eGFP expressing
cells (as a percentage of HO-14-positive neurons) was
18.2 6 4.0 at 1 week (n 5 183), 21.3 6 3.5% at 2 weeks
(n 5 177) and 18.8 6 3.5% at 4 weeks (n 5 151). These
values are not significantly different from each other (1-
way ANOVA, p 5 0.1858). These data indicate that
eGFP expression was not toxic to the neurons, was stable
for up to 4 weeks in vitro and did not interfere with
neuronal differentiation by this method. Furthermore, no
colocalization of eGFP immunoreactivity was observed
with the astrocyte marker GFAP (Fig. 2L–N), indicating
minimal transfer of eGFP protein from the neurons to the
underlying astrocytes, no production of infectious virus
by the transduced neurons, and no differentiation of the
transduced NT2 cells into astrocytes.
Transduced NT2N Cells Survive and Mediate Marker
Gene Expression in the Adult CNS
To determine whether the gene-modified NT2N neu-
rons survive and integrate into the CNS architecture in
the same way as unmodified NT2N neurons, and whether
they maintain expression of the transferred gene, untrans-
duced or SIN-EF-eGFP-transduced NT2 cells were dif-
ferentiated in vitro into NT2N neurons as described (29)
and stereotactically injected into the striatum of adult
nude mice. For these experiments, an unselected (non-
clonal) population of transduced cells was used to bal-
ance individual differences in expression and neurogenic
potential and for a better comparison to unselected un-
transduced cells. We used a highly transduced population
of NT2 cells (76% eGFP1, n 5 348 cells counted) to
generate neurons for transplantation to maximize our
ability to detect the transduced neurons in vivo. Neurons
were generated for transplantation using retinoic acid
treatment as described (29). Transplants were bilateral,
with untransduced neurons on the right and transduced
neurons on the left. Groups of 3 mice were killed at 1,
4, or 22 weeks post-transplant.
Expression of eGFP by NT2N neurons was analyzed
in grafts in paraffin-embedded brains at 1 week and 1
month post-transplantion by in situ hybridization. While
both transduced and untransduced grafts were human
neurofilament-immunoreactive (Fig. 3A, C), only the
transduced grafts hybridized with the eGFP antisense ri-
boprobe (Fig. 3B, D). Neither the transduced nor the un-
transduced grafts hybridized with the control eGFP sense
riboprobe (data not shown). To examine long-term eGFP
expression in vivo, brains harvested at 22 weeks post-
transplantation were frozen and cryosections were ex-
amined for eGFP and neurofilament expression. Grafts
contained within the striatum were consolidated and
showed no evidence of migration beyond the implanta-
tion site. No expansion of graft size was observed, thus
there was no evidence of tumor formation.
Green fluorescence from eGFP expression in trans-
duced grafts of the NT2N neurons was observable after
ethanol fixation and direct examination by fluorescence
microscopy of frozen sections (data not shown). To col-
ocalize cellular eGFP expression in the graft with huNF-
M, sections were reacted with both an anti-eGFP
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Fig. 2. Reporter gene expression was maintained after neuronal differentiation in vitro. NT2N neurons were generated by
culturing a population of transduced undifferentiated NT2 cells on a monolayer of rat astrocytes and analyzed by immunofluo-
rescence. A–D: The arrowhead marks an untransduced NT2N neuron; the arrow marks an eGFP-expressing NT2N neuron. A:
All cellular nuclei in a field of transduced and untransduced NT2N neurons and astrocytes were marked by DAPI (blue). B:
Transduced neurons expressed eGFP in the cell bodies and processes of NT2N neurons (green). C: Processes of both transduced
and untransduced neurons were immunoreactive with anti-neurofilament antibody (HO14, red). D: Colocalization of neurofilament
immunoreactivity and eGFP-immunoreactivity in a transduced neuron. Scale bar in A applies to panels A–D, 20 mm. E–F: High-
power photomicrograph of 2 transduced neurons expressing eGFP (anti-eGFP, in green, panel E) and huNF-M (HO14, in red,
panel F). G–H: High-power photomicrograph of a control untransduced neuron. The nucleus was stained with DAPI (blue, panel
G) and the cell body and processes were immunoreactive with HO14 (red, panel H) but eGFP was not expressed. H: Image was
created by merging the image from the rhodamine filter set (HO14) with the image from the FITC filter set, which in this case
showed no positive eGFP staining. Scale bar in E applies to panels E–H, 10 mm. I–K: Cocultures of NT2N neurons on astrocyte
monolayers 4 weeks after plating. I: Coculture stained with HO-14 (red) showed extensive process outgrowth (compare to panel
C at 1 week after plating). J: Coculture stained with anti-eGFP showed eGFP throughout the cell bodies and apparent bipolar
processes (green). K: Merged image of panels I and J showed colocalization of the neurofilament and eGFP immunoreactivity
in the cell body and processes. I–K, insets: A highly branched transduced neuron at 4 weeks after plating. Scale bars in panel I
and its inset apply to panels I–K and insets, 20 mm. L–N: Cocultures of NT2N neurons on astrocyte monolayers stained with
anti-GFAP (red) and anti-eGFP (green). L: Coculture of untransduced neurons with GFAP-immunoreactive astrocytes (red). M:
Coculture of transduced neurons expressing eGFP (green) with GFAP-immunoreactive astrocytes (red). Scale bar in L applies to
panels L and M, 40 mm. N: Higher power photomicrograph of a transduced neuron expressing eGFP (green) on a monolayer of
astrocytes (GFAP, red). No colocalization of eGFP with GFAP in astrocytes was observed. Scale bar in N, 10 mm.
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Fig. 3. eGFP expression in transduced grafts in vivo. A–D: Immunohistochemistry and in situ hybridization of NT2N
neuronal grafts at 1 week post-transplant. Transduced NT2N neuronal grafts were detected with both anti-neurofilament
antibody HO14 (A) and an eGFP antisense riboprobe (B), whereas the untransduced NT2N neuronal grafts were detected
with HO14 antibody (C) but not the eGFP antisense riboprobe (D). A, C: Nuclei were counterstained with hematoxylin
(blue). Scale bar in A applies to panels A–D, 50 mm. E–G: Immunofluorescent detection of eGFP and huNF-M in NT2N
neuronal grafts at 22 weeks post-transplant. A bright autofluorescent red and green punctate pattern was present along the
needle tracts in both transduced and untransduced grafts, probably representing residual blood/hemosiderin from the injec-
tion. The merged red and green autofluorescent signal appears as yellow in panels E and F and does not colocalize with
cellular eGFP staining. E: An untransduced graft expressed huNF-M (HO14, red) but not green fluorescent protein. F:
Transduced grafts expressed human neurofilament (HO14, red) and the transferred reporter gene, eGFP (anti-eGFP, green).
Scale bar in E and F, 50 mm. G: The majority of the huNF-M-positive (red) NT2N neurons in the center of a transduced
graft continued to express eGFP (green). E–G: Nuclei were counterstained with DAPI (blue). Scale bar in G, 25 mm. H–J:
High-power photomicrograph of a transduced NT2N neuron in vivo expressing eGFP (green, panel H) and huNF-M (red,
panel I). In the merged image (panel J), staining was colocalized in the cell body and in the processes (yellow). Scale bar
in H applies to panels H–J, 10 mm.
antibody and an anti-neurofilament antibody (HO14). Un-
transduced grafts were not eGFP-positive but did show
neurofilament expression surrounding a cluster of nuclei
that indicated the presence of NT2N neurons at the graft
site (Fig. 3E). In the transduced grafts, eGFP-immuno-
reactive cell bodies and huNF-M-immunoreactive fila-
ments were both confined to the region of the graft (Fig.
3F). We examined neurofilament-positive NT2N neurons
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Fig. 4. Schematic representation of a sagittal section of the
mouse brain at approximately 0.25 mm lateral to the midline.
The location of the cortical injury cavity is shown in grey and
the target area for the transplant (medial septum) is marked with
a box. The maximal extent of the injury cavity is shown in this
schematic, however the true center of the injury cavity is lo-
cated approximately 2 mm lateral to this section, overlying the
hippocampus. Abbreviations: MS, medial septum; OB, olfac-
tory bulb; Cb, cerebellum; hc, hippocampus.
in the center of the striatal grafts to determine whether
down-regulation of eGFP expression had occurred. In a
majority of the cells, eGFP expression was visible (Fig.
3G), corresponding to the approximately 75% of cells
that were eGFP-positive prior to injection. Isolated cells
near the edge of the transduced NT2N grafts showed ex-
pression of eGFP immunoreactivity in the cell body and
the processes of these transplanted neurons (Fig. 3H)
with huNF-M in the cytoskeleton and the processes (Fig.
3I) and clear colocalization of the 2 markers of trans-
duced neurons in vivo (Fig. 3J). Transduced and untrans-
duced grafts were approximately the same size at 1 week
and 5.5 months post-transplantation (compare Fig. 3A
and C to 3E and F), and there was no evidence of ne-
crosis near the grafts.
Therapeutic Efficacy of NGF-Expressing NT2N Neurons
in Brain-Injured Mice
To test whether transduced NT2N neurons can contrib-
ute to functional recovery after an injury, we transplanted
NGF-expressing or control NT2N neurons into the CNS
of brain-injured mice (Fig. 4).
To express NGF in NT2N neurons, we constructed a
lentiviral transfer plasmid encoding human NGF-b driven
by the same EF1-a promoter (Fig. 1A). The bioactivity
of NGF encoded by this construct was tested using a
PC12 survival assay (Fig. 5A–C) and a PC12 neurite re-
generation assay (Fig. 5D–F). Withdrawal of serum from
the culture medium of PC12 cells caused .90% cell
death after 3 days (Fig. 5A) that was rescued by addition
of conditioned media from 293T cells transfected with
the NGF transfer plasmid (Fig. 5B), or by recombinant
NGF (Fig. 5C). Recombinant NGF also promoted neurite
outgrowth in primed PC12 cells (Fig. 5D), as previously
described (33). The same effect was obtained with con-
ditioned medium from 293T cells transfected with the
NGF transfer plasmid (Fig. 5E) but not with control me-
dia from untransfected cultures (Fig. 5F), as expected.
The NGF-encoding lentiviral vector was used to trans-
duce cultures of NT2 cells. To determine the percentage
of cells that had been transduced, NGF-transduced and
control untransduced cultures were screened for hNGF
mRNA by in situ hybridization. Similar to the transduc-
tion efficiency with the eGFP lentiviral vector, the NGF
lentiviral vector transduced approximately 80% of the
NT2 cells, as shown by their hybridization with the NGF
antisense riboprobe (Fig. 5G). Control untransduced NT2
cells did not react with the NGF antisense riboprobe (Fig.
5H). Both transduced and untransduced NT2 cells did not
hybridize with the control NGF sense riboprobe (Fig. 5I,
J), indicating that the reaction was specific for NGF
mRNA expressed from the vector genome in the trans-
duced cells.
The amount of NGF secreted by transduced and un-
transduced NT2 cells was measured using an NGF-spe-
cific ELISA (Fig. 5K). NGF-transduced cells secreted
7669 6 913.9 pg NGF/day/105 cells. Untransduced NT2
cells secreted 14.2 6 0.72 ng/day/105 cells, or 540-fold
less NGF than the transduced NT2 cells.
Adult mice (n 5 32) were subjected to brain injury
using a CCI device (35), which produces immediate dam-
age to the cortex and delayed cell death in the underlying
hippocampus. This results in the loss of cholinergic neu-
rons of the medial septum, which are dependent on the
hippocampus for NGF trophic support. Because the sep-
to-hippocampal pathway is important for spatial learning,
we assessed performance of the CCI-injured mice using
the Morris Water Maze test of visuo-spatial learning at 1
month post-injury.
Brain-injured mice or sham-injured (surgery without
injury) mice were subjected to cell transplantation or in-
jection of medium at 24 h after the injury. In brain-in-
jured mice, NGF-transduced or untransduced NT2N neu-
rons were transplanted into the medial septum ipsilateral
to the injury. As controls, sham-injured and brain-injured
animals were injected with an equal volume of the same
medium (serum-free DMEM) that was used to resuspend
the neurons. At 1 month post-transplant, groups of 8 an-
imals were evaluated for their ability to learn the position
of a hidden platform in the Morris Water Maze (Fig. 5L).
The test consisted of 24 trials (8 trials/day 3 3 consec-
utive days), and the time for each mouse to reach the
platform (latency) was measured. It has been demonstrat-
ed that swim speeds and patterns do not differ between
injured and uninjured mice in the CCI model (35). Brain-
injured animals had a marked cognitive deficit compared
to the uninjured animals, indicating a significant injury
effect at 1 month post-injury. Brain-injured animals that
had received transplants of NGF-expressing NT2N neu-
rons into the medial septum performed significantly bet-
ter than brain-injured animals that had received either a
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Fig. 5. Characterization of NGF-expressing NT2 cells and neurobehavioral improvement after NGF-NT2N transplantation
into brain-injured mice. A–C: PC12 survival assay for NGF bioactivity. Serum withdrawal results in the death of PC12 cells
after 72 hours (A). Cells survived in serum-free medium supplemented with either 50 ng/ml recombinant human NGF in the
positive control (B), or 50% conditioned medium from 293T cells transfected with the lentiviral NGF transfer plasmid (C). D–
F: PC12 neurite regeneration assay for NGF bioactivity. PC12 cells extended processes after plating in serum-free medium plus
either 50 ng/ml recombinant human NGF (D) or 50% conditioned medium from NGF-transfected cells (E), but not 50% condi-
tioned medium from control untransfected cells (F). G–J: In situ hybridization histochemistry to detect NGF mRNA in transduced
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NT2 cells. The antisense NGF riboprobe hybridized with ;80% of the transduced NT2 cells (G) but not control untransduced
NT2 cells (H). A control sense riboprobe did not hybridize to either NGF-transduced (I) or untransduced (J) NT2 cells. K:
Quantitation of the amount of NGF secreted by transduced and untransduced NT2 cells. Bar represents standard error of the
mean (n 5 3). L: Latencies to reach the submerged platform in the Morris Water Maze over 24 trials of testing at 1 month post-
injury for brain-injured animals injected with media or untransduced NT2N neurons (grey bars), brain-injured animals injected
with NGF-NT2N neurons (striped bar), or sham-injured animals injected with medium (black bar). Error bars are standard error
of the mean. Sham-injured animals injected with medium had significantly shorter latencies to reach the platform than brain-
injured animals injected with medium, indicating that there was still a cognitive deficit due to the injury after 4 weeks. In the
brain-injured animals treated with NGF-NT2N neurons (striped bar), there was a significant improvement compared to the brain-
injured animals injected with untransduced NT2N neurons (p 5 0.024) or with control medium (p 5 0.036). Multivariate ANOVA
(p , 0.01) followed by a Tukey-Kramer multiple comparison test. *p , 0.05.
transplant of untransduced NT2N neurons (p , 0.05) or
an injection of media (p , 0.05), indicating that the NGF-
expressing cells improved learning and that a neuronal
transplant by itself did not have a therapeutic effect.
DISCUSSION
We show that human neuronal cells that were engi-
neered to express a transferred gene can engraft into the
host CNS architecture, extend processes in a regionally
appropriate manner, and survive and express the trans-
ferred gene for at least 6 months in vivo. Furthermore,
NT2N neurons genetically engineered to express NGF
were able to improve cognitive function when transplant-
ed into brain-injured mice. These data indicate that hu-
man NT2N neurons represent a practical and effective
platform for ex vivo gene therapy in the CNS.
NT2 cells have particular experimental advantages due
to their origin as a clonal cell line that can be easily
propagated in culture. Transduction with a pseudotyped
lentiviral vector was stable, efficient (obviating the need
for a selectable marker), and nontoxic. The ability to
achieve stable gene expression in NT2 cells and NT2N
neurons in this study is primarily due to 3 factors: 1) The
eukaryotic promoter we chose (EF1a) is constitutively
active, in contrast to strong viral promoters which can be
down-regulated. In fact, the commonly used cytomega-
lovirus immediate-early promoter is actively repressed in
NT2 cells (data not shown and [36]); 2) We used an in-
tegrating lentiviral vector that results in the transmission
of the vector genome to daughter cells; and 3) Lentiviral
vectors are very efficient and nontoxic, in contrast to the
toxicity of adenovirus and SFV (V.M-Y.L, unpublished
data), poor infection of NT2 cells and NT2N neurons by
wild-type herpes simplex virus type I (HSV-1) (37), lysis
of NT2 cells by a neuroattenuated strain of HSV-1 (38),
and the inefficiency of AAV [25]). Although recombinant
vaccinia virus (VV) has been successfully used with dif-
ferentiated NT2N neurons without cytotoxicity, VV in-
fection of the NT2 precursor cells was cytotoxic (24).
Furthermore, VV is a nonintegrating virus.
We also found that multiple coding sequences can be
introduced by using multiple vectors (data not shown).
Another alternative is the use of bicistronic or tricistronic
vectors that include regulatable or constitutively active
promoters. Individual cell clones can be isolated, ex-
panded, and characterized for the levels of expression of
the introduced gene, the number of neurons generated
upon exposure to retinoic acid, and the sequence of the
genomic integration site.
Earlier studies showed that cultured NT2N neurons ex-
press markers of immature CNS neurons, including neu-
rofilament proteins and MAP2 (4), APP695 (39), N- and
L-type calcium channels (40), GABA receptors (41), and
acetylcholinesterase (42, 43). Cultured NT2N neurons
form functional synapses in vitro and use both glutama-
tergic and GABAergic neurotransmission (44, 45). When
differentiated NT2N neurons are transplanted and al-
lowed to survive for more than 4 months in vivo in the
CNS of immunodeficient mice, maturation occurs with
the expression of highly phosphorylated NF-H and the
adult form of the microtubule-associated protein, tau (7).
Transplantation of NT2N neurons in or near white matter
tracts provides a permissive environment for axonal out-
growth (7, 16). Genetically modified NT2N neurons
should allow molecular characterization of proteins that
facilitate guidance, axonal outgrowth, and fasciculation
in vitro and in vivo.
Long-term survival of marked neural grafts in vivo
allows the opportunity to investigate several other im-
portant questions in CNS transplant biology. The ability
to identify grafted neurons in live slice cultures will per-
mit electrophysiological characterization of synaptic ac-
tivity (if any) in both immature and mature (.4 month)
transplanted neurons. Synaptic connections between the
transplanted neurons and between the host and the graft
can be investigated. Also, the possibility for the graft to
become an abnormally active epileptogenic focus can be
studied. Marked neurons can also be used to determine
whether guidance cues in the injured brain recruit trans-
planted neurons to the damaged tissue. Finally, down-
regulation of expression of genes transferred by viral vec-
tors has been a long-standing concern in the field of gene
therapy (46). Genetically marked NT2N neurons, which
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are identifiable in vivo with human-specific antibodies,
can be used to examine this issue.
Experimental rodent models of TBI have been shown
to consistently produce both short (days to weeks) and
prolonged (months, up to 1 year) deficits in learning and
memory that can be evaluated using the visuospatial
learning task in the Morris Water Maze (35, 47–52).
These models accurately reproduce many of the most
common cognitive deficits associated with TBI in hu-
mans, including problem solving, learning, and memory
(53–55). Intraparenchymal (directly into the injured cor-
tex) or intracerebroventricular (ICV) administration of
NGF has been shown to have beneficial effects on cog-
nitive outcome in experimental studies using rodent mod-
els of TBI (56–58). However, clinical application of neu-
rotrophin infusions has been problematic due to the
global side effects associated with ICV administration, so
this approach may therefore not be suitable for long-term
therapeutic intervention (59). Our approach using NT2N
neurons as a platform for ex-vivo gene therapy may pro-
vide an advantage for long-term neurotrophin delivery
into selectively vulnerable regions of the injured brain.
It is of interest that the untransduced grafts had no
effect on cognition in this setting. Previous studies in the
traumatically injured CNS (18, 60) also did not find cog-
nitive or motor recovery at 2 or 4 weeks after transplan-
tation of untransduced NT2N neurons in the injured cor-
tex. Borlongan et al (22) described a therapeutic effect
of NT2N grafts in ischemic rats at 1 month post-injury,
but in other models of neurodegenerative disease, thera-
peutic effects of NT2N grafts on motor function were
observed only at more chronic (.10 weeks) post-trans-
plant time points (17, 20). Experimental animals in our
study were analyzed at 4 weeks post-transplant. One po-
tential mechanism to account for the improved Morris
Water Maze performance of the NGF-NT2N grafted an-
imals involves the trophic actions of NGF on medial sep-
tal neurons and preservation of the septo-hippocampal
pathway (57, 61, 62). The behavioral recovery might
therefore be further improved by transplantation of a larg-
er NGF-expressing graft, improved graft survival, or in-
creased NGF secretion from the graft. These results dem-
onstrate that the ability to genetically engineer NT2N
neurons can greatly expand their potential utility as ther-
apeutic tools for the CNS.
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